Allogene Therapeutics (ALLO) Other Working Capital Changes (2018 - 2026)

Allogene Therapeutics has reported Other Working Capital Changes for 9 years, with the latest figure at $316000.0 in Q1 2026.

• Quarterly Other Working Capital Changes rose 117.24% year-over-year to $316000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 140.3% YoY) and the FY2025 annual result came in at $1.1 million, up 118.0% from the prior year.
• Other Working Capital Changes retreated to $316000.0 in Q1 2026 per ALLO's latest filing, from $6.7 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $6.7 million in Q1 2022 and troughed at -$5.7 million in Q3 2022.
• A 5-year average of -$440058.8 and a median of -$986000.0 in 2025 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2023 and 2025: Other Working Capital Changes sank 269250.0% in 2023, then soared 480.01% in 2025.
• Over 5 years, Other Working Capital Changes stood at -$2000.0 in 2022, then tumbled by 269250.0% to -$5.4 million in 2023, then soared by 67.03% to -$1.8 million in 2024, then jumped by 480.01% to $6.7 million in 2025, then slumped by 95.32% to $316000.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $316000.0, $6.7 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.